Compare Bristol-Myers Squibb Co (BMY) vs NetFlix Inc (NFLX) Price & Performance

Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.

BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.

Netflix (NFLX) trades at $73.83, showing modest daily gains of 0.63% but remains in a technical bearish trend. The stock demonstrates strong fundamental performance with Q1 2026 EPS beating expectations at $1.23 versus $0.763 expected, while revenue growth accelerated to 16% year-over-year. Analyst sentiment remains predominantly bullish with 66% buy ratings, though technical indicators signal near-term caution with the stock approaching key support levels.

The investment outlook balances robust fundamentals against technical headwinds. Netflix's expanding advertising business and projected $3 billion in ad revenue by 2026 provide growth catalysts, while competitive pressures and market volatility present risks. With a consensus price target of $103.64 offering 40% upside potential, the stock presents value for long-term investors despite near-term technical weakness.